BlossomHill Therapeutics ... (BLSM)
NasdaqGS: BLSM
· Real-Time Price · USD
16.18
-0.17 (-1.04%)
At close: Aug 14, 2026, 3:59 PM
16.18
+0.00%
After-hours: 7:34 PM
BlossomHill Therapeutics Inc. (BLSM) Stock Price, Analysis & Data
-1.04% (1D)
| Bid | 16.52 |
| Market Cap | 470.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -71.08M |
| Beta | n/a |
| EPS (ttm) | -3.41 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | -0.28 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 16.34 |
| Volume | 323,774 |
| Avg. Volume (20D) | 613,066 |
| Open | 16.31 |
| Previous Close | 16.35 |
| Day's Range | 16.00 - 16.75 |
| 52-Week Range | 15.25 - 17.25 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BLSM
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 7, 2026
Employees 63
Stock Exchange NasdaqGS
Ticker Symbol BLSM
Website https://bhtherapeutics.com
Financial Performance
In 2025, BlossomHill Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -60.55M, an increase of 97.28%.
Financial Statements